3-Week Course of Radiotherapy May Offer Greater Convenience for Patients With Soft Tissue Sarcoma

December 29, 2022Jason HarrisModerately hypofractionated preoperative radiotherapy did not increase risk for major wound complication in patients with soft tissue sarcomas, according to findings from

Updated on: October 17,2023

3-Week Course of Radiotherapy May Offer Greater Convenience for Patients With Soft Tissue Sarcoma

December 29, 2022Jason HarrisModerately hypofractionated preoperative radiotherapy did not increase risk for major wound complication in patients with soft tissue sarcomas, according to findings from

Updated on:October 17,2023

Study identifies skin microbiome as a factor in stem cell transplants

Study identifies skin microbiome as a factor in stem cell transplantsbyMedical University of ViennaCredit: AI-generated imageOrgan damage occurs in up to 70% of patients in the first few months

Updated on: October 30,2023

Study identifies skin microbiome as a factor in stem cell transplants

Study identifies skin microbiome as a factor in stem cell transplantsbyMedical University of ViennaCredit: AI-generated imageOrgan damage occurs in up to 70% of patients in the first few months

Updated on:October 30,2023

Radiotherapy for ductal in situ carcinoma ups mortality risk in invasive second breast cancer

(HealthDay)—For women with primary ductal carcinoma in situ (DCIS), use of radiotherapy (RT) is associated with increased rates of breast cancer-specific mortality for those women who subsequently dev

Updated on: December 22,2023

Radiotherapy for ductal in situ carcinoma ups mortality risk in invasive second breast cancer

(HealthDay)—For women with primary ductal carcinoma in situ (DCIS), use of radiotherapy (RT) is associated with increased rates of breast cancer-specific mortality for those women who subsequently dev

Updated on:December 22,2023

Novel subtype of nasopharyngeal carcinoma and Epstein-Barr virus–associated immune suppression discovered

Updated on: December 21,2023

Novel subtype of nasopharyngeal carcinoma and Epstein-Barr virus–associated immune suppression discovered

Updated on:December 21,2023

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

Updated on: October 15,2023

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

Updated on:October 15,2023

Tumor Profiling Studies Illuminate Nuances Across Malignancies

November 21, 2022Megan HollaschMolecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods ar

Updated on: October 17,2023

Tumor Profiling Studies Illuminate Nuances Across Malignancies

November 21, 2022Megan HollaschMolecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods ar

Updated on:October 17,2023

New study reveals how blood cancer cells escape the immune system's natural killer cells

byUniversity of HelsinkiGraphical abstract. Credit:Immunity(2023). DOI: 10.1016/j.immuni.2023.11.008The advent of T-cell therapies, where cells of the immune system are directed towa

Updated on: January 26,2024

New study reveals how blood cancer cells escape the immune system's natural killer cells

byUniversity of HelsinkiGraphical abstract. Credit:Immunity(2023). DOI: 10.1016/j.immuni.2023.11.008The advent of T-cell therapies, where cells of the immune system are directed towa

Updated on:January 26,2024

MDNA11 Generates Activity, Safety in Advanced Solid Tumors

August 9, 2023Chris RyanTreatment with the long-acting interleukin-2 superkine led to durable tumor control and no dose-limiting toxicities in patients with advanced solid tumors, according to data fr

Updated on: October 12,2023

MDNA11 Generates Activity, Safety in Advanced Solid Tumors

August 9, 2023Chris RyanTreatment with the long-acting interleukin-2 superkine led to durable tumor control and no dose-limiting toxicities in patients with advanced solid tumors, according to data fr

Updated on:October 12,2023

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14, 2023Caroline SeymourNeoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic r

Updated on: October 12,2023

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14, 2023Caroline SeymourNeoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic r

Updated on:October 12,2023

Study points to new possibilities for treating lung cancer patients

by Birgitte Svennevig,University of Southern DenmarkAn EMT-centric investigation of metabolic processes in a comprehensive lung cancer transcriptome profiles collection identified an inverse ass

Updated on: May 25,2024

Study points to new possibilities for treating lung cancer patients

by Birgitte Svennevig,University of Southern DenmarkAn EMT-centric investigation of metabolic processes in a comprehensive lung cancer transcriptome profiles collection identified an inverse ass

Updated on:May 25,2024

Treatment without hormone blockers improves outcomes in solitary prostate cancer metastases

byWolters Kluwer HealthA, Prostate specific antigen (PSA) waterfall plot for surgical metastasis-directed therapy. B, PSA waterfall plot for stereotactic body radiation therapy metastasis-direct

Updated on: December 19,2023

Treatment without hormone blockers improves outcomes in solitary prostate cancer metastases

byWolters Kluwer HealthA, Prostate specific antigen (PSA) waterfall plot for surgical metastasis-directed therapy. B, PSA waterfall plot for stereotactic body radiation therapy metastasis-direct

Updated on:December 19,2023

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on: October 24,2023

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on:October 24,2023